Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new ...

Insulet continues to see adoption of its Omnipod 5 pump—the device that represents Insulet's entrance into hybrid closed-loop technology that makes life easier by automating insulin delivery ...

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create an artificial pancreas system used by diabetics – and claimed that ...

Participants began with an average HbA1c level of 8.1%. After three months, people who used Omnipod 5 improved HbA1c by an ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...

Insulet Corporation’s RADIANT study shows glycaemic improvements with Omnipod 5 automated insulin delivery system: Action, Massachusetts Friday, March 21, 2025, 18:00 Hrs [IST] ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its revolutionary Omnipod 5 ...

Insulin device maker Insulet Corporation (NASDAQ ... guidance of 18% due to revenue outperformance for all product lines. Omnipod revenue of $480.4 million, an increase of 26.3% (+26.5% in ...

Omnipod 5 is designed to be used in tandem ... Research by GlobalData’s Medical Device Database estimates that the insulin pump market brought in more than $7bn in 2024 alone, with that figure ...

Insulet Corporation (NASDAQ: PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with ...

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its intention ...